Open Forum Infectious Diseases, Volume 8, Issue 11, November 2021, ofab358, https://doi.org/10.1093/ofid/ofab358
On July 6, 2021, Open Forum Infectious Diseases published the article “Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection” by Hill, et al. Subsequently, we and the authors learned that one of the largest studies on which this analysis was based was withdrawn due to fraudulent data; additional problems have emerged regarding other studies included in the original paper. An editorial Expression of Concern was first published under this record as the authors revised their analysis for resubmission.
The authors submitted and published a corrected version of the analysis with commentary on assessing trial quality while creating meta-analyses, available to read in OFID: “Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud” by Hill et al., https://doi.org/10.1093/ofid/ofab645. The original analysis has been retracted.
Contributor Information
Andrew Hill, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Anna Garratt, Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK.
Jacob Levi, Department of Intensive Care, University College London Hospital, ULCH NHS Trust, London, UK.
Jonathan Falconer, Department of Infectious Diseases, Chelsea and Westminster Hospital, Imperial NHS Trust, London, UK.
Leah Ellis, Faculty of Medicine, Imperial College London, London, UK.
Kaitlyn McCann, Faculty of Medicine, Imperial College London, London, UK.
Victoria Pilkington, Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK.
Ambar Qavi, Faculty of Medicine, Imperial College London, London, UK.
Junzheng Wang, Faculty of Medicine, Imperial College London, London, UK.
Hannah Wentzel, Faculty of Medicine, Imperial College London, London, UK.